Hypertension and Essential Tremor: A Beta-Blocker Choice Complicated by Raynaud's
A woman with thirty years of mild, ulcer-free Raynaud's phenomenon needs a beta-blocker to help close a persistent blood-pressure gap and control a worsening tremor — but a nonselective agent carries a real, imperfectly-quantified risk of triggering the kind of vasospasm episode she has not had in three decades.
L.F., a 54-year-old woman, has spent most weekends for the past decade at a pottery wheel, working wet clay that leaves her hands damp and cold for hours — exactly the trigger her fingers have reacted to since her Raynaud's phenomenon was diagnosed in her mid-twenties. The Raynaud's has stayed mild and primary the whole time: no digital ulcers, a negative ANA panel at diagnosis, and three decades of managing it with layered gloves and avoiding cold-water glazing when she can. She's otherwise healthy aside from mild hyperlipidemia, treated for several years with a low-dose statin. Her newer problem is a hypertension diagnosis eight months ago — an office reading of 158/94 that repeated on a home cuff — treated first with lisinopril 10 mg. Two months later, follow-up pressures still held at 148/90, so the lisinopril was doubled to 20 mg and amlodipine 5 mg was added. Three months after that, amlodipine was increased to 10 mg, bringing her to 142/88 — better, but still above her goal of under 130/80 — and leaving her with mild bilateral ankle swelling that makes her reluctant to push the dose any higher. At her visit two weeks ago, about two and a half months later, her home readings averaged 136/86 — closer, still short — and she raised something new: a bilateral hand tremor, present mildly for about two years, has worsened over the last four months enough now to affect her control at the wheel and her glaze work.
The tremor matters for more than her pottery. Propranolol carries the AAN's highest evidence grade for essential tremor — Level A, which it shares with primidone — and it would also help close the blood-pressure gap her regimen hasn't closed alone — a two-problems, one-drug argument for a beta-blocker now rather than a fourth, unrelated agent. The complication: propranolol is nonselective, blocking beta-2 receptors in peripheral vasculature as readily as beta-1 receptors in the heart, and beta-2 blockade removes a vasodilating counterbalance that vessels prone to vasospasm may depend on more than most. Cardioselective agents like bisoprolol are generally the safer choice for Raynaud's, but the trade is sharper than it first looks: tremor suppression is thought to be largely beta-2 mediated, so the same receptor blockade that threatens her fingers is the one doing the work on her hands. Selective agents have consistently underperformed propranolol for tremor, and metoprolol's efficacy appeared only at doses high enough to lose its selectivity. And that selectivity is a matter of degree, not an absolute switch — it narrows as the dose rises, and the doses that actually move a resistant blood pressure aren't the lowest ones on the label. Whether that residual beta-2 effect is enough to provoke a meaningful episode in someone whose Raynaud's has stayed mild for thirty years is exactly the judgment call the evidence doesn't settle cleanly — the literature linking beta-blockers to worsened Raynaud's symptoms is real but comes mostly from smaller or older studies, not a trial built to answer this specific question.
Choosing a beta-blocker
Start propranolol. She's already on two antihypertensives and short of goal, and her tremor has crossed from a minor complaint into something interfering with skilled work she cares about — propranolol is one of the two best-evidenced drugs we have for essential tremor, graded highest by the American Academy of Neurology, and it will help her blood pressure at the same time. Her Raynaud's has been mild for thirty years: no ulcers, no hospital visits for it, ever. A theoretical risk shouldn't override a real, twofold benefit in a patient whose disease course has been this stable.
If her Raynaud's history included even one ischemic ulcer or a hospitalization, I'd be having a completely different conversation — this isn't a blanket argument for propranolol in Raynaud's generally, it's specific to how mild hers has actually been.
The selectivity argument is real, but it isn't a clean switch — beta-1 selectivity is dose-dependent, and it erodes as the dose climbs. Bisoprolol's advantage over propranolol at 5 mg is much larger than its advantage at the higher doses actually needed to move a blood pressure that's already proven resistant to two other agents. I'd rather start with the drug that keeps more of its selectivity at the dose we'll likely need, and treat propranolol as the next step, not the first one.
That's not a reason to rule propranolol out permanently — and I'd put real odds on it coming to that, since bisoprolol has no tremor evidence of its own and the selective agents that have been studied read as second-best. If it doesn't touch the tremor at an adequate dose, the calculation changes. It's a sequencing argument, not a prohibition.
I've followed her Raynaud's for most of those thirty years, and it's genuinely been unremarkable — no ulcers, no digital ischemia, nothing beyond seasonal discomfort. That history makes me less worried than the textbook warning alone would suggest. But I'll be honest about what the evidence actually is: the reports linking beta-blockers to worsened Raynaud's symptoms are mostly small, older studies, not a trial built to answer exactly this question — which means neither side of this argument gets to claim more certainty than it has. Start with bisoprolol, but pair it with an explicit plan: she tracks color changes and any new numbness or pain in her fingers, and we recheck her hands specifically at the four-week visit, not just her blood pressure.
Agreed: start bisoprolol 5 mg once daily, continue lisinopril 20 mg and amlodipine 10 mg unchanged, and build in an explicit hand-monitoring plan — self-tracked color changes, any new numbness or pain — reviewed specifically at the four-week follow-up alongside her blood pressure and tremor severity.
Not agreed, and left as an explicit fork rather than a shared assumption:
The plan holds as written — no reason to introduce propranolol's added vasospasm risk once the two-problems-one-drug goal is already met.
The primary care physician would move to propranolol next, with the hand-monitoring plan tightened rather than abandoned. The pharmacologist and rheumatologist would rather add primidone for the tremor specifically and hold a nonselective agent in reserve.
Nobody set odds on which branch is more likely. What they did agree on: whichever direction this goes, the plan keeps her hands under explicit watch rather than assuming the theoretical risk simply won't apply to her.